

Synthesis of an Urea-substituted Selenoisobutyric Acid Isostere of the Peroxisome Proliferator-activated Receptor α Selective Agonist

Hoosang Hwang,^{†,‡} Hyukjae Choi,[†] Sang-Jip Nam,[†] Jaeyoung Ko,[†]
Jungyeob Ham,[§] Jungwook Chin,^{†,‡,*} and Heonjoong Kang^{†,‡,*}

[†]Center for Marine Natural Products and Drug Discovery, School of Earth and Environmental Sciences, Seoul National University, NS-80, Seoul 151-747, Korea

[‡]Research Institute of Oceanography, Seoul National University, Seoul 151-741, Korea

*E-mail: jwchin97@snu.ac.kr (J. Chin); hjkang@snu.ac.kr (H. Kang)

[§]Korea Institute of Science and Technology, Gangneung Institute, Gangneung 210-340, Korea

Received August 16, 2011, Accepted September 15, 2011

Key Words : PPAR α , GW7647, Bioisosterism, Alkyl selenide

Peroxisome Proliferator-Activated Receptor α (PPAR α), a major regulator of energy homeostasis discovered in 1990, is present at high density in the liver and regulates the expression of genes involved in fatty acid β -oxidation.¹ As research on its function has been localized to animal experiments, the function of PPAR α in humans is still unclear. Past studies revealed PPAR α participation in tumorigenesis,² inflammation^{3,4} and atherosclerosis.⁵ Therefore, selective agonists of PPAR α are expected to be potential antitumor, anti-inflammatory and anti-atherosclerotic agents. Fibrates were the first generation of PPAR α modulators (Figure 1) GlaxoSmithKline (GSK) then developed a series of urea-substituted thioisobutyric acids (ureido-TiBAs),⁶ which were synthesized using a parallel-array synthetic method. Ureido-TiBA derivatives synthesized from the compounds GW7647 and GW9578 were found to be effective for heart disease caused by hypertension and high-cholesterol *in vivo* (Figure 2).

In particular, GW7647 demonstrated superior potency with \sim 200-fold selectivity over the other PPAR subtypes (EC₅₀ = 6 nM for human PPAR α).⁶ In addition, the administration of GW7647 to rats for 4 days decreased triglyceride and serum apolipoprotein CIII levels by 60% and 40%, respectively, and increased HDL-cholesterol levels by 60%. In this note, we shortly and efficiently synthesized a novel isosteric selenium substitution of ureido-selenoisobutyric

acid of the PPAR α agonist and compared its PPAR α activity. Isosterism is a useful strategy for molecular modification and is a rational approach in drug design.⁷ Isosteric analogs possess an equally well-established biological potency in terms of protein-receptor interactions.⁸ As a proof-of-concept, sulfur-selenium bioisosterism was applied to GW7647 because molecular modeling study suggested a bulkier element at the sulfur fit the receptor better.⁹

During the course of one-pot synthetic studies of alkyl aryl selenides, we developed an *in situ* one-pot synthetic method that is used for the protection of the amine group in aryl bromides with alkylmagnesium bromide.^{10,11} Thus, we set out to develop a method for the formation of an aryl alkyl selenide (such as compound **2**) with an amine substituent that could be used to prepare various ureido-selenoisobutyric acids via a simple and efficient synthetic route.

In our reaction, the starting material **1** is commercially available. 4-bromophenethylamine⁶ is more expensive than 4-bromobenzeneselenol. But our protocol for preparing **2** is cheaper and shorter than that of the GSK protocol.⁶ Although we could not directly detect the transition state during the reaction, intermediates for synthesis of the target




Figure 1. Chemical structures of fibrate compounds.




Figure 2. Chemical structures of GW7647 and GW9578, synthetic PPAR α agonists.

Table 1. Selectivity of PPAR α ligands

Compounds	hPPAR α (EC ₅₀ , μ M)	hPPAR δ (EC ₅₀ , μ M)	hPPAR γ (EC ₅₀ , μ M)
6	0.003	8.4	i.a. ^a
GW7647	0.007	6.8	1.5


^aEC₅₀ values are higher than 1 μ M.

compound **2** could be generated at each step of the reaction. Therefore, we proposed that the integrity of the *in situ* protected amine [-N(MgCl)₂ moiety] in the reaction solvent is successfully maintained during both the lithium-halogen exchange and the selenium insertion reaction. As far as the nucleophilic reactivity of the selenium and amine anions in the intermediate **1t** are concerned, the selenium anion was more reactive to *t*-butyl bromoisobutyrate than the amine anion. The *t*-butyl bromoisobutyrate, however, did not react with the lithium selenolate **1t**, enabling us to successfully run the reaction with a base under traditional thermal reflux condition in one pot and to give of the titled compound **2**, which was directly used in the following step. Treatment of **2** with 4-cyclohexanecarboxylic acid, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBT·H₂O) in CH₂Cl₂ at room temperature for 12 h gave amide **3** in high yield. We improved the reaction yield using EDC as the coupling reagent instead of

N,N'-Diisopropylcarbodiimide (DIC). The secondary alkyl amine **4** was prepared from amide **3** through the general reduction of borane, which was accomplished using excess 1 N BH₃·THF without any additional solvent at room temperature for 1 day. The rest of the transformation consisted of isourea-formation on the secondary amine, and hydrolysis of the *tert*-butyl ester. The final compound, ureido-selenoisobutyric acid (**6**), displayed higher potency (EC₅₀ = 3 nM) and selectivity than GW7647 (Table 1). In summary, we successfully synthesized 2-{4-[2-(4-Cyclohexyl-butyl-amine)-ethyl]-phenylselenanyl}-2-methyl-propionic acid *tert*-butyl ester, a key intermediate for the synthesis of ureido-selenoisobutyric acid, in 70% yield. From this intermediate, we obtained the desired compound **6** in 32% overall yield. We also report the *in vitro* activity of a novel isosteric selenium PPAR α highly selective agonist.

Experimental Section

General. All reactions were performed in oven- and flame-dried glassware under nitrogen atmosphere. Air and moisture sensitive reagents and solvents were transferred *via* syringes or cannula, and they were introduced into the reaction vessel through a rubber septum. Chemicals obtained from commercial sources were used without further purification. Flash column chromatography was carried out on



Scheme 1. Reagents and conditions: (a) (i) ^tPrMgCl (2.0 equiv), THF, rt for 15 min.; (ii) -78 °C, *t*-BuLi (2.0 equiv) for 30 min.; (iii) selenium powder, -78 °C to -10 °C for 2 h.; (iv) vacuum, MeOH, KOH, BrC(CH₃)₂CO₂*t*-Bu, 80 °C for 2 h.; (b) 4-cyclohexanecarboxylic acid, EDC, HOBT, rt for 15 h (70%); (c) 1 M BH₃·THF, rt for 1 day (65%); (d) cyclohexylisocyanate, CH₂Cl₂, rt for 18 h (85%); (e) 50% TFA/CH₂Cl₂, rt for 4 h (82%).

silica gel (230-400 mesh). Analytical thin-layer chromatography (TLC) was performed with silica gel 60 F254. TLC plates were visualized with UV light and 5% ammonium dimolybdate or *p*-anisaldehyde in ethanol with heat. $^1\text{H-NMR}$ (300 MHz) in CDCl_3 was recorded on a Bruker Avance III 400 MHz NMR spectrometer and chemical shifts (δ) were expressed in ppm downfield from the internal tetramethylsilane or with reference to residual CHCl_3 . The purity of compounds was assessed by HPLC/MS spectra, which were recorded on a Finnigan LTQ LC/MS system.

2-{4-[2-(4-Cyclohexyl-butylamino)-ethyl]-phenylselenanyl}-2-methyl-propionic Acid tert-butyl Ester, Compound 3. To a solution of 4-bromophenethylamine (400 mg, 2.0 mmol) in anhydrous THF (20 mL) was slowly added $^i\text{PrMgCl}$ (2.0 M solution in diethyl ether, 2.0 mL, 4.0 mmol) at 0 °C for 10 min under N_2 . After 30 min, *t*-BuLi (1.7 M solution in pentane, 2.4 mL, 4.0 mmol) was slowly added at -78 °C for 20 min and the reaction mixture was stirred for an additional 30 min. Selenium powder (158 mg, 2.0 mmol) was added at once and the reaction mixture was slowly warmed to -10 °C for 2 h. After the reaction was complete, the solvent was completely removed by evaporation under atmospheric conditions. To a solution of the residual product in MeOH (20 mL) was added KOH (117.8 mg, 2.1 mmol) at rt and then heated at 60 °C for another 2 h. After this time, the reaction mixture was poured into a saturated NH_4Cl solution (35 mL) and was extracted with EtOAc (3 \times 30 mL). The combined organic layer was washed with H_2O , dried (MgSO_4), filtered off and then concentrated on a rotary evaporator. To crude compound 2 (342 mg) and cyclohexanebutanoic acid (171 mg, 1.0 mmol) in dried CH_2Cl_2 was added 1-hydroxybenzotriazole (HOBT· H_2O) (205 mg, 1.5 mmol) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC, 576 mg, 3.0 mmol). The reaction mixture was then stirred at room temperature for 12 h. Next, the reaction mixture was sequentially washed with saturated NaHCO_3 , 1 N HCl and brine solution, and then the organic layer was dried over anhydrous MgSO_4 . After the solvent was evaporated under reduced pressure, the residue was purified by silica gel chromatography using 30% ethyl acetate in hexane to afford as a white solid (350 mg, 70%). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.55 (d, 2H, $J = 7.9$ Hz), 7.14 (d, 2H, $J = 7.9$ Hz), 5.43 (s, brs, 1H), 3.53 (q, 2H, $J = 6.7$ Hz), 2.82 (t, 2H, $J = 6.9$ Hz), 2.10 (t, 2H, $J = 7.5$ Hz), 1.70-1.53 (m, 7H), 1.51 (s, 6H), 1.43 (s, 9H), 1.28-1.14 (m, 6H), 0.87 (m, 2H).

2-{4-[2-(4-Cyclohexyl-butylamino)-ethyl]-phenylselenanyl}-2-methyl-propionic Acid tert-butyl Ester, Compound 4. To a solution of 3 (494 mg, 1.0 mmol) was added a 1M solution of borane in THF (20 mL, 20.0 mmol), and the reaction mixture was allowed to stand for 1 day without stirring. Excess borane was destroyed by the careful addition of methanol and the resulting solution heated at reflux for 30 min. After the addition of *n*-butanol (5 mL) the solvent was evaporated and the residue was purified by silica gel chromatography using 10% methanol in ethyl acetate to afford a yellow viscous liquid (312 mg, 65%). $^1\text{H NMR}$ (300

MHz, CDCl_3) δ 7.57 (d, 2H, $J = 8.0$ Hz), 7.17 (d, 2H, $J = 8.0$ Hz), 3.13-2.67 (m, 7H), 1.69 (m, 6H), 1.50-1.43 (m, 15H), 1.28-1.16 (m, 6H), 0.82 (m, 2H).

2-(4-{2-[3-Cyclohexyl-1-(4-cyclohexyl-butyl)-ureido]-ethyl}-phenylselenanyl)-2-methyl-propionic Acid tert-butyl Ester, Compound 5. To a solution of 4 (240 mg, 0.5 mmol) in dried CH_2Cl_2 (3 mL) was added cyclohexylisocyanate (126 mg, 1.0 mmol) and then the reaction mixture was stirred at room temperature for 18 h. Then, the solvent was evaporated and the residue was purified by silica gel chromatography using 5% methanol in CH_2Cl_2 to afford as a white solid (257 mg, 85%). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.54 (d, 2H, $J = 8.0$ Hz), 7.16 (d, 2H, $J = 8.0$ Hz), 4.05 (d, 1H, $J = 7.7$ Hz), 3.63 (m, 1H), 3.42 (t, 2H, $J = 7.1$ Hz), 3.05 (t, 2H, $J = 7.2$ Hz), 2.84 (t, 2H, $J = 7.5$ Hz), 1.90 (m, 2H), 1.67 (m, 8H), 1.42-1.01 (m, 30H), 0.86 (m, 2H).

2-(4-{2-[3-Cyclohexyl-1-(4-cyclohexyl-butyl)-ureido]-ethyl}-phenylselenanyl)-2-methyl-propionic Acid, Compound 6. To a solution of 5 (302 mg, 0.5 mmol) in CH_2Cl_2 (3 mL) was slowly added trifluoroacetic acid (3 mL) and then the reaction mixture was stirred at room temperature for 4 h. On completion of the reaction, the solvent was evaporated and the residue was purified by silica gel chromatography using 5% methanol in CH_2Cl_2 to afford 6 as a white solid (225 mg, 82%). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.53 (d, 2H, $J = 7.7$ Hz), 7.18 (d, 2H, $J = 7.8$ Hz), 4.07 (d, 1H, $J = 7.6$ Hz), 3.54 (m, 1H), 3.43 (t, 2H, $J = 7.0$ Hz), 3.04 (t, 2H, $J = 7.3$ Hz), 2.79 (t, 2H, $J = 6.9$ Hz), 1.87 (m, 2H), 1.68-0.95 (m, 23H), 1.54 (s, 6H), 0.86 (m, 2H). LC/MS (ESI+) Calcd for $\text{C}_{29}\text{H}_{46}\text{N}_2\text{O}_3\text{Se}$ [M+H] $^+$: m/z 548.26. Found: m/z 549.28.

Acknowledgments. We are grateful to members of our laboratory. This work was supported by the Marine Biotechnology Program, Ministry of Land, Transport and Maritime Affairs (MLTM) and in part the BK21 program from the Ministry of Education, Science and Technology (MEST), Korea. We thank John Lee for administrative assistance.

References

1. Issemann, I.; Green, S. *Nature* **1990**, *347*, 645.
2. Hasmall, S.; James, N.; Hedley, K.; Olsen, K.; Roberts, R. *Arch. Toxicol.* **2001**, *75*, 357.
3. Staels, B.; Koenig, W.; Habib, A. *Nature* **1998**, *393*, 790.
4. Delerive, P.; Gervois, P.; Fruchart, J. C.; Staels, B. *J. Biol. Chem.* **2000**, *275*, 36703.
5. Fu, T.; Kashireddy, P.; Borensztajn, J. *Biochem. J.* **2003**, *373*, 941.
6. Brown, P. J.; Winegar, D. A.; Plunket, K. D.; Moore, L. B.; Lewis, M. C.; Wilson, J. G.; Sundseth, S. S.; Koble, C. S.; Wu, Z.; Chapman, J. M.; Lehmann, J. M.; Kliever, S. A.; Willson, T. M. *J. Med. Chem.* **1999**, *42*, 3785.
7. Patani, G. A.; LaVoie, E. J. *Chem. Rev.* **1996**, *96*, 3147.
8. Lima, L. M.; Barreiro, E. J. *Curr. Med. Chem.* **2005**, *12*, 23.
9. Chin, J.; Hong, J. Y.; Lee, J.; Hwang, H.; Ko, H.; Choi, H.; Hahn, D.; Ko, J.; Nam, S. J.; Tak, J.; Ham, J.; Kang, H. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 7239.
10. Ham, J.; Cho, S. J.; Ko, J.; Chin, J.; Kang, H. *J. Org. Chem.* **2006**, *71*, 5781.
11. Chin, J.; Tak, J.; Hahn, D.; Yang, I.; Ko, J.; Ham, J.; Kang, H. *Bull. Korean Chem. Soc.* **2009**, *30*, 496.